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Twelve sessions were conducted.
Results.– Amnesic effect on pain may occur during mobilization.
Flexion: 958 active.
Pain: 0/10 at rest and walking.
Improving the quality of walking with a smooth and not increase walking speed
without technical assistance.
Resumption of his previous 26 months work after the diagnosis of CRPS-I.
Scintigraphy: net regression process CRPS-I detected in his right knee in 2010.
Regularization of all households hyperactive.
Discussion and conclusion.–This would be for the benefit of nitrous oxide in the
mobilization of a stiff joint including CRPS-I through a permitting algo-
functional improvement and joints that enabled our patient to return to his
previous work.
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Introduction.– Intrathecal ziconotide has shown its efficiency in chronic
resistant pain, we studied the association with baclofene in spastic pain
management.
Patients.– Seven patients, 4 female, 3 male, average age 54.3 years old [39; 75]
have been treated with continuous intrathecal infusion of baclofene, ziconotide
and morphine. Four had a failed back surgery syndrome, 1 peripherical nerve
lesion, 1 spine injury, 1 cerebral palsy. Ziconotide has been introduced after the
failure of an intrarachidian morphine + baclofene treatment.
Results.– The average decrease of pain intensity after we began the ziconotide
treatment was equal to 31 mm on visual analog pain scale, from 68 to 37 mm
efter ziconotide introduction. Ziconotide adding had no effect on spasticity
which was already efficiently managed by intrathecal baclofene. The average
follow-up was 13.3 months [2; 26 months]. Average ziconotide posologies were
3.1 mg per day [1.25; 5.7 mg per day] and 342 mg per day [43; 1800 mg per day]
for baclofene. Ziconotide had to be stopped for 3/7 (43%) because of side
effects, with a full recovery after treatment interruption. One patient kept
auditory hallucination but did not want any posology modification since he was
satisfied with the antalgic level. Most of the side effects occurred during the first
semester of our using of ziconotide due to a too fast dose increase. The
commonest side effects were: nausea, dizziness, ataxia, visual and/or auditory
hallucination. No treatment failure has been noticed for two years. Initial
treatment administration has to be as low as possible (1 mg per day in our
population) in order to obtain antalgic effect without major side effects. A slight
increase of doses (+0.3 mg per week) allows pain management without side
effects.
Conclusion.– Ziconotide in association with intrathecal baclofene is a good way
to deal with chronic pain with spasticity.
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The algodystrophy is a regional pain syndrome, characterized by complex
neurovascular abnormalities. Pregnancy appears through mechanical factors
promote dystrophy of the lower limbs. We report a case of bilateral hip
dystrophy diagnosed during postpartum.
This is a 31-year-old woman, primipara, who presented in the third quarter of
pregnancy (35 weeks gestation) mechanical bilateral groin pain with functional
impairment. She has consulted in postpartum (4 days after birth). The review
noted a limp, functional impairment with a VAS pain 70%. Standard
radiographs postpartum showed speckled locoregional demineralization hips.
MRI confirmed the diagnosis of CRPS hips. The patient took analgesic
treatment with a discharge and rest for 3 months. She has not received
bisphosphonates because she breastfeeding. Disease duration was 24 weeks.
The evolution was marked by the persistence of residual pain (VAS 20%)
without sequelae.
The analysis of our results compared to literature, allows to identify the main
characteristics of this variety of reflex sympathetic dystrophy: gradual onset in
the second or third trimester, location in the hip alone or associated with other
locations [1–3]. MRI is currently the modality of choice for the early and
differential diagnosis [1,3]. The course is generally favorable [3].
Algodystrophy during pregnancy is rare and is often misunderstood. MRI have
an important place in the diagnosis of this disease. The safety of
bisphosphonates during pregnancy and lactation remains to be demonstrated.
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Objective.– The study of the literature concerning the treatment of piriformis
muscle syndrome (PMS) to validate the role of botulinum toxin injections
performed after failure of medical management and rehabilitation. The few
reported series confirm the results significantly superior to placebo injections
and even repeated anesthetics and/or corticosteroids. The piriformis muscle
belongs to the deep part of the gluteal region where the need for radiological
identification. Our team couples the ultrasound with electromyography
detection, allowing the latter through an active lateral rotation maneuver (in
a subject supine on the healthy side) to optimize the injection site. Ultrasound,
with constant technical progress and the development of new sensors, allows
very interesting morphological evaluation of the muscle and its relationship
with the main sciatic nerve. The objective of this study was to validate the
clinical and ultrasonographic markers compared to CT and anatomical data.
Patients and methods.– Five patients supported for SMP received botulinum
toxin injections under ultrasound and CT with a minimum of 3 months between
each injection, the second injection performed because of insufficient
improvement of symptoms.
Results.– The clinical markers of projection of the piriformis muscle is defined
by a triangle whose base joins the posterior superior iliac spine and the upper
part of the inter-gluteal fold, and whose summit is next to the upper pole of the
greater trochanter. Ultrasound (abdominal convex probe tone) body muscle is
visualized on the lateral edge of the sacrum with a depth of 4.8 cm for the
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